Neuroinflammation

BOCA RATON, Fla., May 15, 2026 INmune Bio announced the publication of positive Phase 2 MINDFuL trial results for...

PARIS and CAMBRIDGE, UK, May 13, 2026 AndzonBio2 announced a strategic collaboration with the ALBORADA Drug Discovery Institute (ADDI)...

GAITHERSBURG, Md., United States – May 2026 Neuraly Inc. has announced that the first patient has been dosed in...

PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...

BASEL, Switzerland, April 13, 2026 Roche has announced that its Elecsys® Neurofilament Light Chain (NfL) blood test has received...

Boston, MA, USA – April 1, 2026 In a promising development for age-related cognitive decline and neurodegenerative disorders, Tiziana...

JUPITER, Fla., Feb. 23, 2026 — Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system...

Jupiter, Florida | January 28, 2026 — Jupiter Neurosciences, Inc., a clinical-stage pharmaceutical company, announced a strategic expansion of...

Irvine, Calif. – October 23, 2025 Researchers at the University of California, Irvine have uncovered a previously unrecognised molecular...

HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...